181 related articles for article (PubMed ID: 36964635)
21. MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.
Tang Z; Fang Y; Du R
Biochem Biophys Res Commun; 2019 Apr; 512(2):331-337. PubMed ID: 30885433
[TBL] [Abstract][Full Text] [Related]
22. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.
Wang X; Sun Q; Chen C; Yin R; Huang X; Wang X; Shi R; Xu L; Ren B
Oncotarget; 2016 Feb; 7(7):8029-42. PubMed ID: 26771237
[TBL] [Abstract][Full Text] [Related]
23. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
25. DCLRE1B promotes tumor progression and predicts immunotherapy response through METTL3-mediated m6A modification in pancreatic cancer.
Li L; Wang F; Deng Z; Zhang G; Zhu L; Zhao Z; Liu R
BMC Cancer; 2023 Nov; 23(1):1073. PubMed ID: 37936074
[TBL] [Abstract][Full Text] [Related]
26. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
27. PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
Fang Y; Zhang X; Guo Y; Dong Y; Liu W; Hu X; Li X; Gao D
Cell Biochem Biophys; 2023 Sep; 81(3):569-576. PubMed ID: 37572218
[TBL] [Abstract][Full Text] [Related]
28. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
30. A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity.
Ding JT; Yu XT; He JH; Chen DZ; Guo F
Front Genet; 2022; 13():912003. PubMed ID: 35783266
[No Abstract] [Full Text] [Related]
31. Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types.
Hu A; Wang Y; Tian J; Chen Z; Chen R; Han X; Chen Y; Liu T; Chen Q
Front Oncol; 2022; 12():947054. PubMed ID: 36505822
[TBL] [Abstract][Full Text] [Related]
32. Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers.
Peng D; Wei C; Zhang X; Li S; Liang H; Zheng X; Jiang S; Han L
Cancer Cell Int; 2021 Oct; 21(1):566. PubMed ID: 34702252
[TBL] [Abstract][Full Text] [Related]
33.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
34. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
36. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
Luo Q; Li X; Li J; Kong X; Zhang J; Chen L; Huang Y; Fang L
Int J Oncol; 2013 Oct; 43(4):1212-8. PubMed ID: 23900351
[TBL] [Abstract][Full Text] [Related]
37. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
[TBL] [Abstract][Full Text] [Related]
38. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
[TBL] [Abstract][Full Text] [Related]
39. PEX13 is a potential immunotherapeutic indicator and prognostic biomarker for various tumors including PAAD.
Dong P; Du X; Yang T; Li D; Du Y; Wei Y; Sun J
Oncol Lett; 2023 Dec; 26(6):512. PubMed ID: 37920431
[TBL] [Abstract][Full Text] [Related]
40. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
